Publication, Part of National Diabetes Audit

National Diabetes Audit - Report 1 Care Processes and Treatment Targets 2018-19, Full Report

Audit, Survey, Other reports and statistics

Publication Date:: 10 Dec 2020
Geographic Coverage:: England, Wales
Geographical Granularity:: Clinical Commissioning Groups, GP practices, Hospital Trusts, NHS Health Boards
Date Range:: 01 Jan 2018 to 31 Mar 2019

Summary

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This report details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. This report follows the NDA short report publication in December 2019, which provided the top level findings for the 2018-19 audit, along with local level data made available to services in a timely manner that can help drive improvements in the quality of diabetes care locally. A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections. Included within this publication is the National Diabetes Insulin Pump Audit interactive reporting and supporting information. It provides information on people with Type 1 diabetes on an insulin pump at National, LHB, and Specialist Diabetes Service level for the 2018-19 audit period.

Note: An error was identified in the original release of the National Diabetes Insulin Pump Audit 2018-19, Interactive Report for Specialist Services in England. The number of people with Type 1 diabetes in the 'HbA1c values' section was overstated and showed the total number of people with any type of diabetes seen at the service. This has been corrected and replaced with a new version of the report on 23 December 2020.

GP practice participation in England and Wales stands at 98.0 per cent for 2018-19.
Diabetes specialist service participation increased from 101 in 2017-18 to 112 in 2018-19.
In England, the percentage of people who had all eight care process checks during 2018-19 stands at 40.8 per cent for people with Type 1 diabetes (42.9 per cent in 2017-18) and 54.3 per cent for people with Type 2 and other diabetes (58.8 per cent in 2017-18).
In Wales, the percentage of people who had all eight care process checks during 2018-19 stands at 23.3 per cent for people with Type 1 diabetes (24.7 per cent in 2017-18) and 44.7 per cent for people with Type 2 and other diabetes (45.9 per cent in 2017-18).
In England, the percentage of people who met the new all three treatment targets* during 2018-19 stands at 19.6 per cent for people with Type 1 diabetes (18.9 per cent in 2017-18) and 40.5 per cent for people with Type 2 and other diabetes (40.2 per cent in 2017-18).
In Wales, the percentage of people who met the new all three treatment targets* during 2018-19 stands at 15.1 per cent for people with Type 1 diabetes (15.2 per cent in 2017-18) and 33.6 per cent for people with Type 2 and other diabetes (35.0 per cent in 2017-18).

* HbA1c value ≤ 58mmol/mol, blood pressure ≤140/80 and, for people who fall into the combined prevention of cardiovascular disease risk group, is receiving statins.